Rationale and design of a phase II trial of pyrotinib in combination with nab-paclitaxel as adjuvant therapy for N0/N1mi, HER2 + early breast cancer (PHAEDRA)

BACKGROUND: The de-escalation treatment in patients with low-risk HER2-positive early breast cancer (eBC) is an attractive strategy to avoid unnecessary treatment and improve the quality of life of patients. Pyrotinib, a novel irreversible pan-HER2 tyrosine kinase inhibitor (TKI), has shown efficacy...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Changjun, Zhou, Yidong, Lin, Yan, Mao, Feng, Guan, Jinghong, Zhang, Xiaohui, Shen, Songjie, Wang, Xuejing, Zhang, Yanna, Pan, Bo, Zhong, Ying, Peng, Li, Cao, Xi, Yao, Ru, Zhou, Xingtong, Xu, Chi, Xu, Ying, Sun, Qiang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8919536/
https://www.ncbi.nlm.nih.gov/pubmed/35287613
http://dx.doi.org/10.1186/s12885-022-09346-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8919536/
https://www.ncbi.nlm.nih.gov/pubmed/35287613
http://dx.doi.org/10.1186/s12885-022-09346-1

Ejemplares similares